A peptide derivative serves as a fibroblast growth factor 2 antagonist in human gastric cancer

• DOI: 10.1007/s13277-015-3435-x
• Publication Date: 2015-04-18T14:20:37Z
• Authors: Lei Fan; Wulan Li; Shilong Ying; Lingyi Shi; Zhe Wang; Gaozhi Chen; Hui Ye; Xiaoping Wu; Jianzhang Wu; Guang Liang; Xiaokun Li
• Keywords: 0301 basic medicine; Carcinogenesis; Protein Conformation; Molecular Dynamics Simulation; Surface Plasmon Resonance; 3. Good health; Molecular Docking Simulation; Kinetics; 03 medical and health sciences; Immobilized Proteins; Stomach Neoplasms; Cell Line, Tumor; Humans; Fibroblast Growth Factor 2; Neoplasm Invasiveness; Peptides; Cell Proliferation; Protein Binding

Fibroblast growth factor 2 (FGF2) plays a critical role in tumorigenesis and progression of solid tumor is upregulated gastric carcinoma serum. Therefore, it regarded as potential therapeutic target human cancer. Suppression bioactivities FGF2 may contribute to cancer therapy. Herein, we obtained novel FGF2-binding peptide derivative (named P32), which originated from previously isolated P7 with poor stability. We proved that P32, had half-life plasma up 12 h, enhanced stability exerted strong inhibitory effect on FGF2-induced cell proliferation invasion lines. Further investigations revealed the underlying anti-proliferation mechanisms P32 vitro included arresting FGF2-stimulated cells at G0/G1 phase reducing activation AKT Erk1/2 cascades. The has improved stability, relatively safe, have FGF2-driven